The S100B/RAGE Axis in Alzheimer's Disease
Authors:
Open Access
- 21 June 2010
- journal article
- review article
- Published by Wiley in Cardiovascular Psychiatry and Neurology
- Vol. 2010, 1-11
Abstract
Increasing evidence suggests that the small EF-hand calcium-binding protein S100B plays an important role in Alzheimer's disease. Among other evidences are the increased levels of both S100B and its receptor, the Receptor for Advanced Glycation Endproducts (RAGEs) in the AD diseased brain. The regulation of RAGE signaling by S100B is complex and probably involves other ligands including the amyloid beta peptide (A), the Advanced Glycation Endproducts (AGEs), or transtheyretin. In this paper we discuss the current literature regarding the role of S100B/RAGE activation in Alzheimer's disease.Keywords
This publication has 157 references indexed in Scilit:
- The dysregulation of intracellular calcium in Alzheimer diseaseCell Calcium, 2010
- Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's diseaseGlia, 2009
- Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's diseaseBrain Research, 2008
- New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's DiseaseNeurotherapeutics, 2008
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetesMicrovascular Research, 2008
- The Extracellular Region of the Receptor for Advanced Glycation End Products Is Composed of Two Independent Structural UnitsBiochemistry, 2007
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- S100B in brain damage and neurodegenerationMicroscopy Research and Technique, 2003
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996